Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Nat Commun. 2021 Nov 25;12(1):6909. doi: 10.1038/s41467-021-26980-8.
There is an urgent need for innovative methods to reduce transmission of bloodborne pathogens like HIV and HCV among people who inject drugs (PWID). We investigate if PWID who acquire non-pathogenic bloodborne viruses like anelloviruses and pegiviruses might be at greater risk of acquiring a bloodborne pathogen. PWID who later acquire HCV accumulate more non-pathogenic viruses in plasma than matched controls who do not acquire HCV infection. Additionally, phylogenetic analysis of those non-pathogenic virus sequences reveals drug use networks. Here we find first in Baltimore and confirm in San Francisco that the accumulation of non-pathogenic viruses in PWID is a harbinger for subsequent acquisition of pathogenic viruses, knowledge that may guide the prioritization of the public health resources to combat HIV and HCV.
目前非常需要创新的方法来降低艾滋病毒和丙型肝炎病毒等血源性病原体在注射毒品者(PWID)中的传播。我们研究了感染非致病性血源性病毒(如细小病毒和戊型肝炎病毒)的 PWID 是否更有可能感染血源性病原体。与未感染 HCV 的匹配对照者相比,后来感染 HCV 的 PWID 在血浆中积累了更多的非致病性病毒。此外,对这些非致病性病毒序列的系统发育分析揭示了药物使用网络。在这里,我们首次在巴尔的摩发现,并在旧金山证实,PWID 中非致病性病毒的积累是随后感染致病性病毒的先兆,这一知识可能指导公共卫生资源的优先次序,以对抗 HIV 和 HCV。